METHYLPREDNISOLONE SODIUM SUCCINATE
Clinical safety rating: avoid
CYP3A4 inducers (eg phenytoin) may decrease efficacy and inhibitors may increase effects Can cause hyperglycemia and adrenal suppression with prolonged use.
Methylprednisolone sodium succinate is a glucocorticoid that binds to the glucocorticoid receptor, leading to modulation of gene expression. It suppresses inflammation by inhibiting phospholipase A2, reducing prostaglandin and leukotriene synthesis; it also decreases cytokine production and immune cell activity.
| Metabolism | Hepatic metabolism primarily via CYP3A4; methylprednisolone is metabolized to inactive metabolites that are excreted in urine. |
| Excretion | Renal: ~75% as metabolites (20-30% unchanged); Biliary/Fecal: minor (<10%) |
| Half-life | Terminal elimination half-life: 2.5-3.5 hours (plasma); biological half-life: 12-36 hours (based on pharmacodynamic effects due to intracellular receptor binding and gene regulation) |
| Protein binding | 68-77% bound to albumin and corticosteroid-binding globulin (CBG/transcortin) |
| Volume of Distribution | 0.7-1.5 L/kg (indicates wide distribution into tissues; crosses placenta and enters breast milk) |
| Bioavailability | Oral: 80-90% (varies with formulation); IM: 100% (prodrug converted rapidly); IV: 100% |
| Onset of Action | IV: 1-2 hours (peak effect in 4-8 hours); IM: 4-8 hours; Oral: 3-6 hours |
| Duration of Action | IV: 12-36 hours (duration of adrenal suppression and anti-inflammatory effect); IM: 4-8 days (depot effect); Oral: 12-36 hours |
| Molecular Weight | 496.53 Da (as sodium succinate salt; parent methylprednisolone MW 374.47 Da) |
Intravenous (IV) or intramuscular (IM) injection: 10-40 mg initially, then 10-40 mg every 6-12 hours. For pulse therapy: 1 g IV over 30 minutes daily for 3-5 days.
| Dosage form | INJECTABLE |
| Renal impairment | No dose adjustment required for GFR ≥30 mL/min. For GFR <30 mL/min, use with caution and monitor for fluid retention; no specific dose adjustment recommended. |
| Liver impairment | Child-Pugh A: No adjustment. Child-Pugh B: Reduce dose by 50% or use with caution. Child-Pugh C: Avoid use or use lowest effective dose with close monitoring. |
| Pediatric use | IV/IM: 0.5-1.7 mg/kg/day divided every 6-12 hours. For pulse therapy: 15-30 mg/kg IV over 30 minutes daily for 3 days, maximum 1 g/day. |
| Geriatric use | Start at lower end of dosing range (e.g., 10 mg) due to increased risk of osteoporosis, hyperglycemia, and immunosuppression. Monitor for adverse effects. |
| 1st trimester | Use only if clearly needed; associated with increased risk of cleft palate (odds ratio 1.3-1.7) and preterm birth. Consider lowest effective dose. |
| 2nd trimester | May be used for maternal benefit; monitor for fetal growth restriction and adrenal suppression; prenatal corticosteroid therapy for lung maturation is not typically indicated in second trimester. |
| 3rd trimester | Use only if clearly needed; late pregnancy exposure may cause neonatal adrenal suppression; avoid high doses near term if possible. |
Clinical note
CYP3A4 inducers (eg phenytoin) may decrease efficacy and inhibitors may increase effects Can cause hyperglycemia and adrenal suppression with prolonged use.
| FDA category | Positive |
| Placental transfer | Readily crosses the placenta; metabolized to active prednisolone in placenta; fetal concentrations ~10-30% of maternal levels. Transplacental passage decreases with higher protein binding. |
■ FDA Black Box Warning
None.
| Common Effects | Nausea Taste change Vomiting Diarrhea Constipation Cough Dizziness Weakness Headache Cold extremities Slow heart rate Numbness of extremity Increased potassium level in blood Decreased blood pressure |
| Serious Effects |
Systemic fungal infections (except when used for life-threatening conditions with amphotericin B)Hypersensitivity to methylprednisolone or any excipientIntrathecal administration (contraindicated due to risk of arachnoiditis)Live or attenuated virus vaccines (concurrent use)Idiopathic thrombocytopenic purpura (IM use only)
| Precautions | Increased risk of infections and masking of signs of infection, Adrenal suppression and insufficiency upon withdrawal, especially after prolonged therapy, Cushing's syndrome, hyperglycemia, diabetes mellitus, Osteoporosis and increased fracture risk, Gastrointestinal perforation, peptic ulcer, pancreatitis, Behavioral and mood disturbances (e.g., euphoria, insomnia, psychosis), Increased intracranial pressure and pseudotumor cerebri, Ocular effects: cataracts, glaucoma, central serous chorioretinopathy, Cardiovascular: hypertension, thromboembolism, myocardial rupture in post-MI patients, Prolonged use may impair growth in children, Live or live-attenuated vaccines are contraindicated during immunosuppressive doses |
Loading safety data…
| Breastfeeding | Excreted into breast milk in small amounts (relative infant dose ~1.5% of maternal weight-adjusted dose). Considered compatible with breastfeeding; no known adverse effects in term infants. Monitor for potential adrenal suppression with prolonged high maternal doses. Prefer interval dosing after nursing. |
| Lactation Rating | L2 (Safer) |
| Teratogenic Risk | First trimester: Cleft palate risk increased (OR 1.3-3.4) with systemic use. Second/third trimesters: Fetal growth restriction, adrenal suppression, preterm birth risk. Avoid high doses. Use lowest effective dose for shortest duration. |
| Fetal Monitoring | Maternal: Blood glucose, blood pressure, electrolyte levels, signs of infection. Fetal: Ultrasound for growth (if prolonged use), neonate monitoring for adrenal insufficiency if maternal use in late pregnancy. |
| Fertility Effects | May impair ovulation (suppression of gonadotropins). Reversible upon discontinuation. Use may delay conception. No permanent effects. |
| Food/Dietary | Avoid grapefruit juice as it may increase corticosteroid concentrations. Limit sodium intake to reduce fluid retention and hypertension. Consume potassium-rich foods (bananas, oranges) if hypokalemia occurs. Alcohol may increase risk of GI irritation; avoid or limit. |
| Clinical Pearls | Administer IV push over at least 1 minute or as IVPB due to risk of arrhythmias with rapid administration. For high-dose pulse therapy (e.g., 500 mg-1 g/day), monitor for electrolyte disturbances, hypertension, and signs of infection. Use lowest effective dose and shortest duration. Taper dose when discontinuing after prolonged therapy to avoid adrenal insufficiency. May cause acute pancreatitis or steroid-induced myopathy. Consider H2 blocker or PPI for GI prophylaxis in high doses. |
| Patient Advice | Do not stop taking this medication suddenly; follow your doctor's tapering schedule. · Report any signs of infection (fever, sore throat) as this drug can mask infections. · Avoid live vaccines while on this medication. · Monitor for symptoms of high blood sugar (increased thirst, urination) especially if diabetic. · Report any unusual weight gain, swelling, or mood changes. · Take with food or milk to reduce stomach upset. · Wear a medical alert bracelet indicating corticosteroid use. |